Specialty drugs are biologics—"drugs derived from living cells"—that are injectable or infused (although some are oral medications). They are used to treat complex or rare chronic conditions like cancer, rheumatoid arthritis, hemophilia, H.I.V. psoriasis, inflammatory bowel disease, and hepatitis C. Specialty drugs are often biologics—"drugs derived from living cells"—that are oral medications. As soon as possible, patients should receive the right medicine. Some businesses have personalized treatment groups that are obviously highly passionate about the topic, even though they may go by the moniker "advances in genetic organizations" or "stratified medicine" groups. However, recent research that looked into the worldwide drug pipeline inventory of around 20 large businesses found that relatively few of them had what may be called stratified or customized medication. We have been striving to put that framework in place. Personalized medicine concepts have been or are now being included within early drug development advice, which will eventually be used to affect policy on patient screening or clinical trial strategies in later phases.
Vladlen Slepak
University of Miami, United States
Axel H Schonthal
University of Southern California, United States
Bernd Blobel
University of Regensburg, Germany
Consolato M Sergi
University of Alberta, Canada
Luis Jesus Villarreal Gomez
Universidad Autónoma de Baja California, Mexico
Anil Pareek
Anand Pharmacy College, India
Saad Tayyab
UCSI University, Malaysia
Lan Wang
Paretor LLC, United States
Ravi P Sahu
Wright State University, United States
Tanuja Tummala
Harrisburg University of Science and Technology, United StatesSubmit your abstract Today
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, University of Alberta, Canada
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Precision diagnostics: Effectiveness of innovative imaging technologies for early detection of lung cancers
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Design and characterization of gum arabic buccal films for protein drug delivery
Krisztian Pamlenyi, University of Szeged, Hungary
Title : Advancing EGFR-targeting macrocyclic peptide-drug conjugates to target KRAS-mutant solid tumors: Design, synthesis, and preclinical evaluations
Akash Panja, Ariel University, Israel